Without disclosing the financial details, a press release from GVK Bio said the deal enables GVK BIO to expand its service offering to a broader base of organisations and gives expertise in biologics services besides significant US presence.
The acquisition provides Aragen with the ability to expand its service offerings, access to GVK BIO's global sales force and access to new markets, the release said.
D S Brar, Chairman, GVK BIO said as an increasing number of biotech and pharmaceutical companies focus on protein-based therapeutics and bio-similars, the acquisition of Aragen Bioscience will strategically enhance GVK BIO's ability to offer high quality R&D services to the industry from a seamless integrated platform.